{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tazarotene&page=2",
    "query": {
      "intervention": "tazarotene",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tazarotene&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T17:11:17.528Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00829049",
      "title": "Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tazarotene Cream 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Adapalene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2007-10",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2012-09-12",
      "last_synced_at": "2026-09-28T17:11:17.528Z",
      "location_count": 1,
      "location_summary": "Fremont, California",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829049"
    },
    {
      "nct_id": "NCT04071756",
      "title": "Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Hand-Foot Skin Reaction (HFSR)"
      ],
      "interventions": [
        {
          "name": "Topical Tazarotene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2019-12-30",
      "completion_date": "2022-07-14",
      "has_results": true,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-09-28T17:11:17.528Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04071756"
    },
    {
      "nct_id": "NCT05282771",
      "title": "A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%",
          "type": "DRUG"
        },
        {
          "name": "Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 402,
      "start_date": "2021-04-16",
      "completion_date": "2022-02-10",
      "has_results": false,
      "last_update_posted_date": "2022-03-16",
      "last_synced_at": "2026-09-28T17:11:17.528Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05282771"
    },
    {
      "nct_id": "NCT01094717",
      "title": "Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Acitretin 25Mg Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Excimer laser",
          "type": "DEVICE"
        },
        {
          "name": "Tazarotene 0.1% Gel,Top",
          "type": "DRUG"
        },
        {
          "name": "Sham excimer laser",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2010-01",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-09-28T17:11:17.528Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01094717"
    },
    {
      "nct_id": "NCT00667589",
      "title": "Sorafenib-induced Hand- Foot Skin Reaction Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hand-foot Skin Reaction",
        "Rash"
      ],
      "interventions": [
        {
          "name": "urea 40% cream",
          "type": "DRUG"
        },
        {
          "name": "fluocinonide 0.05% cream",
          "type": "DRUG"
        },
        {
          "name": "tazarotene 0.1% cream",
          "type": "DRUG"
        },
        {
          "name": "bland emollient cream (Udderly smooth® Udder Cream)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2008-06",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-06-05",
      "last_synced_at": "2026-09-28T17:11:17.528Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00667589"
    },
    {
      "nct_id": "NCT03341910",
      "title": "A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "DFD-03 Lotion, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Tazorac Cream, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "DFD-03 Vehicle Lotion 0%",
          "type": "DRUG"
        },
        {
          "name": "Tazorac Vehicle Cream 0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Reddy's Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2017-08-21",
      "completion_date": "2018-05-18",
      "has_results": true,
      "last_update_posted_date": "2020-08-17",
      "last_synced_at": "2026-09-28T17:11:17.528Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03341910"
    },
    {
      "nct_id": "NCT03599193",
      "title": "A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tazarotene Lotion, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene Cream, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Reddy's Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2017-10-04",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-03-01",
      "last_synced_at": "2026-09-28T17:11:17.528Z",
      "location_count": 2,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03599193"
    },
    {
      "nct_id": "NCT02160678",
      "title": "Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene Cream, 0.1 %",
          "type": "DRUG"
        },
        {
          "name": "Tazorac Cream, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G & W Laboratories Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 1741,
      "start_date": "2014-05",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-03",
      "last_synced_at": "2026-09-28T17:11:17.528Z",
      "location_count": 1,
      "location_summary": "Arlington Hts., Illinois",
      "locations": [
        {
          "city": "Arlington Hts.",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02160678"
    },
    {
      "nct_id": "NCT02886715",
      "title": "A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tazarotene Cream 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Tazorac®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fougera Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 1110,
      "start_date": "2016-09-21",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-09-28T17:11:17.528Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02886715"
    },
    {
      "nct_id": "NCT01616654",
      "title": "Dose Range Study of CD5789 in Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "CD5789 25 µg/g cream",
          "type": "DRUG"
        },
        {
          "name": "CD5789 50 µg/g cream",
          "type": "DRUG"
        },
        {
          "name": "CD5789 100 µg/g cream",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene 0.1% gel",
          "type": "DRUG"
        },
        {
          "name": "Vehicle cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 304,
      "start_date": "2012-06-20",
      "completion_date": "2014-06-12",
      "has_results": true,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-09-28T17:11:17.528Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Marina del Rey",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01616654"
    }
  ]
}